Key points
- ~A$674,000 minimum contracted purchases over three years
- Minimum purchases increase from ~A$139,000 in Year 1 to ~A$310,000 in Year 3
- New European commercial lead appointed to accelerate adoption
Full summary
Memphasys Limited (ASX: MEM) has signed a three-year exclusive distribution agreement with INVIDO LAB s.r.o., a specialist IVF supplier, to expand its European commercial footprint. The agreement covers the Czech Republic, Slovakia, and Kazakhstan, securing minimum contracted purchases of ~A$674,000 over three years. The minimum purchase commitments increase progressively from ~A$139,000 in Year 1 to ~A$310,000 in Year 3, providing a defined pathway to growing recurring revenue as Felix adoption builds. INVIDO will lead the commercial development of Felix across the contracted territories, leveraging its existing relationships with IVF clinics and fertility specialists. Memphasys has also appointed Arne Schierau as Director, Commercial Operations Europe, to strengthen its European commercial capability.
Guidance
Memphasys expects minimum contracted purchases of ~A$674,000 over three years.
Outlook
Memphasys remains confident in securing further commercial relationships in priority international markets.